The SARS-CoV-2 pandemic poses challenges to global healthcare systems, impacting the care of COVID-19 patients and causing disruptions in various medical disciplines, including dermatology. Urgent measures, initiated almost two years ago, aimed to prioritize COVID-19 cases, resulting in a backlog of non-urgent consultations. Dermatology practices were considered potential vectors of COVID-19 transmission, leading to the suspension of non-urgent consultations. The ongoing threat from evolving virus variants has hindered the restoration of normal healthcare flows. In response, an alternative system is imperative for efficient and timely diagnosis and remote patient monitoring. The imbalance in dermatologist-to-patient ratios, especially in Spain and other European countries, accentuates the need for such a system. Delayed diagnosis of skin conditions, including potentially life-threatening melanoma, and exacerbation of chronic diseases during the pandemic underscore the urgency. Currently, no reliable tools exist for remote pathology diagnosis, emphasizing the importance of implementing an innovative solution. Human limitations in quantifying parameters and inherent biases in patient-reported measurement scales further impede accurate assessments. The inadequacy of existing methods, coupled with the reluctance of patients to seek in-person consultations during the pandemic, highlights the necessity for advanced diagnostic tools. The study advocates for the clinical validation of an artificial intelligence tool, Legit.Health, designed to grade disease activity in dermatological patients. Artificial intelligence, particularly Computer Aided Diagnosis (CAD) systems, offers a promising avenue. These systems, leveraging artificial intelligence and image processing, enhance the interpretation of medical images, demonstrating competence comparable to medical experts.